On July 25, 2024 Sanofi reported strong performance with 10% sales growth; 2024 guidance upgraded (Press release, Sanofi, JUL 25, 2024, View Source [SID1234645091]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q2 sales growth of 10.2% at CER and business EPS(1) of €1.73

Dupixent sales up 29.2% to €3,303 million; target of ~€13 billion in 2024 unchanged
Pharma launches up 80.4% to €689 million, led by ALTUVIIIO, Nexviazyme, Rezurock, and Sarclisa
Vaccines sales -4.8% due to COVID-19 sales in 2023
Opella (former Sanofi Consumer Healthcare) up 9.6%, driven by the Qunol acquisition
Research and Development expenses grew 5.5%
Selling, general and administrative expenses grew 4.9%, substantially less than sales growth
Business EPS(1) of €1.73, down 0.6% reported and up 4.0% at CER
IFRS EPS of €0.89, down 22.6% reported
Q2 pipeline progress

Three regulatory approvals; Dupixent COPD (EU, July), Kevzara pJIA (US), Altuvoct hemophilia A (EU)
Four regulatory submissions, including fitusiran in hemophilia A/B and Sarclisa in multiple myeloma
Increasing pipeline news flow over 2024-2025, including 12 phase 3 data readouts

Other key updates

Sanofi ranked world’s 7th most sustainable company by TIME Magazine
Opella (Consumer Healthcare) intended separation on track with previously communicated timelines*
2024 business EPS guidance upgraded

2024 business EPS(1) to be stable at CER(2), an upgrade from a low single-digit percentage decrease previously, underpinned by accelerated delivery of Sanofi’s pipeline-driven transformation. Applying the average July 2024 exchange rates, the currency impact on 2024 business EPS is c.-5.5% to -6.5%.

Paul Hudson, Chief Executive Officer, commented:

"We are continuing our strong performance in 2024 and delivered broad-based, double-digit sales growth in the second quarter. We also made important progress in our pipeline of new medicines, including approvals for Dupixent in COPD, Kevzara in pediatric arthritis and ALTUVIIIO (EU) in hemophilia A. With the EU approval in COPD, Dupixent is the first-ever biologic medicine approved in this debilitating disease impacting hundreds of thousands of patients globally. As we accelerate our focused mid- and late-stage pipeline, we started a number of new phase 2 and phase 3 studies that will benefit patients in the future. We are well on track, delivering on our strategic priorities for Sanofi to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Underpinned by accelerated delivery of Sanofi’s transformation, we upgrade our earnings per share guidance for 2024."

Q2 2024 Change Change
at CER H1 2024 Change Change
at CER
IFRS net sales reported € 10,745 m +7.8% +10.2% € 21,209 m +5.1% +8.4%
IFRS net income reported € 1,113 m -22.4% — € 2,246 m -34.5% —
IFRS EPS reported € 0.89 -22.6% — € 1.80 -34.3% —
Free cash flow(3) € 854 m -46.4% — € 545 m -82.6% —
Business operating income € 2,813 m +3.2% +8.3 % € 5,656 m -6.7% +1.4%
Business net income(1) € 2,161 m -0.7% +4.0 % € 4,380 m -10.2% -2.3%
Business EPS(1) € 1.73 -0.6% +4.0% € 3.51 -10.0% -2.3%